Search

Your search keyword '"Van Roon, J.A.G."' showing total 31 results
Start Over Author "Van Roon, J.A.G."
31 results on '"Van Roon, J.A.G."'

4. sj-docx-2-car-10.1177_19476035221098167 – Supplemental material for The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review

Author

van Helvoort, E.M., van der Heijden, E., van Roon, J.A.G., Eijkelkamp, N., and Mastbergen, S.C.

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 110323 Surgery, 110604 Sports Medicine, FOS: Health sciences, 69999 Biological Sciences not elsewhere classified, 110314 Orthopaedics
Abstract

Supplemental material, sj-docx-2-car-10.1177_19476035221098167 for The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review by E.M. van Helvoort, E. van der Heijden, J.A.G. van Roon, N. Eijkelkamp and S.C. Mastbergen in CARTILAGE

Published
2022
Full Text
View/download PDF

5. sj-docx-1-car-10.1177_19476035221098167 – Supplemental material for The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review

Author

van Helvoort, E.M., van der Heijden, E., van Roon, J.A.G., Eijkelkamp, N., and Mastbergen, S.C.

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 110323 Surgery, 110604 Sports Medicine, FOS: Health sciences, 69999 Biological Sciences not elsewhere classified, 110314 Orthopaedics
Abstract

Supplemental material, sj-docx-1-car-10.1177_19476035221098167 for The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review by E.M. van Helvoort, E. van der Heijden, J.A.G. van Roon, N. Eijkelkamp and S.C. Mastbergen in CARTILAGE

Published
2022
Full Text
View/download PDF

6. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity

Author

Kormelink, T. Groot, Tekstra, J., Thurlings, R.M., Boumans, M.H.J., Vos, K., Tak, P.P., Bijlsma, J.W.J., Lafeber, F.P.J.G., Redegeld, F.A., and van Roon, J.A.G.

Subjects
Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Patient outcomes, Rheumatoid arthritis -- Research, Immunoglobulins -- Physiological aspects, Immunoglobulins -- Research, B cells -- Physiological aspects, B cells -- Research, Health
Published
2010

7. Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study

Author

van Woerkom, J.M., Kruize, A.A., Geenen, R., van Roon, E.N., Goldschmeding, R., Verstappen, S.M.M., van Roon, J.A.G., and Bijlsma, J.W.J.

Subjects
Sjogren's syndrome -- Diagnosis, Sjogren's syndrome -- Development and progression, Sjogren's syndrome -- Care and treatment, Leflunomide -- Dosage and administration, Leflunomide -- Complications and side effects, Leflunomide -- Research, Health
Published
2007

8. Interleukin-7 induced immunopathology in arthritis

Author

Hartgring, S.A.Y., Bijlsma, J.W.J., Lafeber, F.P.J.G., and van Roon, J.A.G.

Subjects
Interleukins -- Analysis, Arthritis -- Development and progression, Immunopathology -- Reports, Health
Published
2006

9. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis

Author

Affandi, A.J., Carvalheiro, T., Ottria, A., Broen, J.C.A., Bossini-Castillo, L., Tieland, R.G., Bon, L.V., Chouri, E., Rossato, M., Mertens, J.S., García, S., Pandit, A., De Kroon, L.M.G., Christmann, R.B., Martín, J., Van Roon, J.A.G., Radstake, Timothy R. D. J., Marut, W., Affandi, A.J., Carvalheiro, T., Ottria, A., Broen, J.C.A., Bossini-Castillo, L., Tieland, R.G., Bon, L.V., Chouri, E., Rossato, M., Mertens, J.S., García, S., Pandit, A., De Kroon, L.M.G., Christmann, R.B., Martín, J., Van Roon, J.A.G., Radstake, Timothy R. D. J., and Marut, W.

Abstract

Objectives: Systemic sclerosis (SSc) is an autoimmune disease with unknown pathogenesis manifested by inflammation, vasculopathy and fibrosis in skin and internal organs. Type I interferon signature found in SSc propelled us to study plasmacytoid dendritic cells (pDCs) in this disease. We aimed to identify candidate pathways underlying pDC aberrancies in SSc and to validate its function on pDC biology. Methods: In total, 1193 patients with SSc were compared with 1387 healthy donors and 8 patients with localised scleroderma. PCR-based transcription factor profiling and methylation status analyses, single nucleotide polymorphism genotyping by sequencing and flow cytometry analysis were performed in pDCs isolated from the circulation of healthy controls or patients with SSc. pDCs were also cultured under hypoxia, inhibitors of methylation and hypoxia-inducible factors and runt-related transcription factor 3 (RUNX3) levels were determined. To study Runx3 function, Itgax-Cre:Runx3 mice were used in in vitro functional assay and bleomycin-induced SSc skin inflammation and fibrosis model. Results: Here, we show downregulation of transcription factor RUNX3 in SSc pDCs. A higher methylation status of the RUNX3 gene, which is associated with polymorphism rs6672420, correlates with lower RUNX3 expression and SSc susceptibility. Hypoxia is another factor that decreases RUNX3 level in pDC. Mouse pDCs deficient of Runx3 show enhanced maturation markers on CpG stimulation. In vivo, deletion of Runx3 in dendritic cell leads to spontaneous induction of skin fibrosis in untreated mice and increased severity of bleomycin-induced skin fibrosis. Conclusions: We show at least two pathways potentially causing low RUNX3 level in SSc pDCs, and we demonstrate the detrimental effect of loss of Runx3 in SSc model further underscoring the role of pDCs in this disease.

Published
2019

11. IL4-10 fusion protein has chondroprotective, anti-inflammatory and potentially analgesic effects in the treatment of osteoarthritis

Author

Steen-Louws, C, Popov-Celeketic, Jelena, Mastbergen, Simon C, Coeleveld, K, Hack, C Erik, Eijkelkamp, N., Tryfonidou, M, Spruijt, S., van Roon, J.A.G., Lafeber, F.P.J.G., Steen-Louws, C, Popov-Celeketic, Jelena, Mastbergen, Simon C, Coeleveld, K, Hack, C Erik, Eijkelkamp, N., Tryfonidou, M, Spruijt, S., van Roon, J.A.G., and Lafeber, F.P.J.G.

Abstract

OBJECTIVE: Effective disease-modifying drugs for osteoarthritis (DMOAD) should preferably have chondroprotective, anti-inflammatory, and analgesic activity combined in a single molecule. We developed a fusion protein of IL4 and IL10 (IL4-10 FP), in which the biological activity of both cytokines is preserved. The present study evaluates the chondroprotective, anti-inflammatory, and analgesic activity of IL4-10 FP in in vitro and in vivo models of osteoarthritis.METHODS: Human osteoarthritic cartilage tissue and synovial tissue were cultured with IL4-10 FP. Cartilage proteoglycan turnover and release of pro-inflammatory, catabolic, and pain mediators by cartilage and synovial tissue were measured. The analgesic effect of intra-articularly injected IL4-10 FP was evaluated in a canine model of osteoarthritis by force-plate analysis.RESULTS: IL4-10 FP increased synthesis (p=0.018) and decreased release (p=0.018) of proteoglycans by osteoarthritic cartilage. Release of pro-inflammatory IL6 and IL8 by cartilage and synovial tissue was reduced in the presence of IL4-10 FP (all p<0.05). The release of MMP3 by osteoarthritic cartilage and synovial tissue was decreased (p=0.018 and 0.028) whereas TIMP1 production was not significantly changed. Furthermore, IL4-10 FP protected cartilage against destructive properties of synovial tissue mediators shown by the increased cartilage proteoglycan synthesis (p=0.0235) and reduced proteoglycan release (p=0.0163). Finally, intra-articular injection of IL4-10 FP improved the deficient joint loading in dogs with experimentally induced osteoarthritis.CONCLUSION: The results of current preliminary study suggest that IL4-10 FP has DMOAD potentials since it shows chondroprotective and anti-inflammatory effects in vitro, as well as potentially analgesic effect in a canine in vivo model of osteoarthritis.

Published
2018

12. IL4-10 fusion protein has chondroprotective, anti-inflammatory and potentially analgesic effects in the treatment of osteoarthritis

Author

Orthopedie en neurochirurgie, dCSCA RMSC-1, Steen-Louws, C, Popov-Celeketic, Jelena, Mastbergen, Simon C, Coeleveld, K, Hack, C Erik, Eijkelkamp, N., Tryfonidou, M, Spruijt, S., van Roon, J.A.G., Lafeber, F.P.J.G., Orthopedie en neurochirurgie, dCSCA RMSC-1, Steen-Louws, C, Popov-Celeketic, Jelena, Mastbergen, Simon C, Coeleveld, K, Hack, C Erik, Eijkelkamp, N., Tryfonidou, M, Spruijt, S., van Roon, J.A.G., and Lafeber, F.P.J.G.

Published
2018

16. Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation

Author

Bikker, A., Kruize, A.A., Wurff-Jacobs, K.M., Peters, R.P., Kleinjan, M., Redegeld, F.A.M., de Jager, W., Lafeber, F.P.J.G., van Roon, J.A.G., Immunopharmacology, Sub Immunopharmacology, and Pharmacology

Abstract

OBJECTIVES: To investigate the potential synergy of IL-7-driven T cell-dependent and TLR7-mediated B cell activation and to assess the additive effects of monocyte/macrophages in this respect. METHODS: Isolated CD19 B cells and CD4 T cells from healthy donors were co-cultured with TLR7 agonist (TLR7A, Gardiquimod), IL-7, or their combination with or without CD14 monocytes/macrophages (T/B/mono; 1 : 1 : 0,1). Proliferation was measured using 3H-thymidine incorporation and Ki67 expression. Activation marker (CD19, HLA-DR, CD25) expression was measured by FACS analysis. Immunoglobulins were measured by ELISA and release of cytokines was measured by Luminex assay. RESULTS: TLR7-induced B cell activation was not associated with T cell activation. IL-7-induced T cell activation alone and together with TLR7A synergistically increased numbers of both proliferating (Ki67+) B cells and T cells, which was further increased in the presence of monocytes/macrophages. This was associated by up regulation of activation markers on B cells and T cells. Additive or synergistic induction of production of immunoglobulins by TLR7 and IL-7 was associated by synergistic induction of T cell cytokines (IFNgamma, IL-17A, IL-22), which was only evident in the presence of monocytes/macrophages. CONCLUSIONS: IL-7-induced CD4 T cell activation and TLR7-induced B cell activation synergistically induce T helper cell cytokine and B cell immunoglobulin production, which is critically dependent on monocytes/macrophages. Our results indicate that previously described increased expression of IL-7 and TLR7 together with increased numbers of macrophages at sites of inflammation in autoimmune diseases like RA and pSS significantly contributes to enhanced lymphocyte activation.

Published
2014

18. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients

Author

Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., Domínguez, M.D.C., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep Infectieziekten Immunologie

Published
2013

20. Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation

Author

Immunopharmacology, Sub Immunopharmacology, Pharmacology, Bikker, A., Kruize, A.A., Wurff-Jacobs, K.M., Peters, R.P., Kleinjan, M., Redegeld, F.A.M., de Jager, W., Lafeber, F.P.J.G., van Roon, J.A.G., Immunopharmacology, Sub Immunopharmacology, Pharmacology, Bikker, A., Kruize, A.A., Wurff-Jacobs, K.M., Peters, R.P., Kleinjan, M., Redegeld, F.A.M., de Jager, W., Lafeber, F.P.J.G., and van Roon, J.A.G.

Published
2014

22. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., Domínguez, M.D.C., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., and Domínguez, M.D.C.

Published
2013

24. Critical proinflammatory role of thymic stromal lymphopoietin and its receptor in experimental autoimmune arthritis.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Hartgring, S.A.Y., Willis, C.R., Dean, C.E., Broere, F., van Eden, W., Bijlsma, J.W.J., Lafeber, F.P.J.G., van Roon, J.A.G., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Hartgring, S.A.Y., Willis, C.R., Dean, C.E., Broere, F., van Eden, W., Bijlsma, J.W.J., Lafeber, F.P.J.G., and van Roon, J.A.G.

Published
2011

26. Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fcgamma receptor I on monocytes.

Author

Infection & Immunity, MS Reumatologie/Immunologie/Infectie, CTI, Wijngaarden, S., van de Winkel, J.G.J., Bijlsma, J.W.J., Lafeber, F.P.J.G., van Roon, J.A.G., Infection & Immunity, MS Reumatologie/Immunologie/Infectie, CTI, Wijngaarden, S., van de Winkel, J.G.J., Bijlsma, J.W.J., Lafeber, F.P.J.G., and van Roon, J.A.G.

Published
2008

27. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction

Author

Circulatory Health, Infection & Immunity, CTI, MS Reumatologie/Immunologie/Infectie, Centraal Diagnostisch Laboratorium, Lebbink, R.J., van den Berg, M.C., de Ruiter, T., Raynal, N., van Roon, J.A.G., Lenting, P.J., Jin, B., Meyaard, L., Circulatory Health, Infection & Immunity, CTI, MS Reumatologie/Immunologie/Infectie, Centraal Diagnostisch Laboratorium, Lebbink, R.J., van den Berg, M.C., de Ruiter, T., Raynal, N., van Roon, J.A.G., Lenting, P.J., Jin, B., and Meyaard, L.

Published
2008

31. Diversity of regulatory T cells to control arthritis

Author

van Roon, J.A.G., Bijlsma, J.W.J., and Lafeber, F.P.J.G.

Abstract

During follow-up of the suppressive functions of CD4^+ T helper (Th) 2 cells in recent years, the suppressive capacities of newly recognised CD4^+ Th cells with more widespread suppressive potential have been extensively investigated. These Th cells, collectively termed regulatory T cells, are characterised by the secretion of specific cytokines, such as interleukin (IL)-10 (Tr1 Th cells), transforming growth factor (TGF)@b (Th3 cells) or the constitutive expression of CD25 (naturally occurring T regulatory cells, nTregs). The balance of these regulatory T cells with pro-inflammatory effector T cells, such as Th1 (interferon (IFN)@c secreting), Th17 (IL-17 secreting) and CD25^- Th cells, has been shown to be of pivotal importance for the development and persistence of autoimmune diseases. The high potential of regulatory T cells (in particular nTregs), to efficiently suppress several arthritic responses both in humans and in animal models of arthritis, make them therapeutic targets of interest in arthritic conditions such as rheumatoid arthritis.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results